Jan 28, 2016 9:05 am EST SCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections
Dec 1, 2015 5:09 pm EST SCYNEXIS, Inc. Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis
Nov 13, 2015 9:03 am EST SCYNEXIS, Inc. Reports Third Quarter 2015 Financial Results and Provides Company Update
Nov 12, 2015 8:30 am EST SCYNEXIS, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating Intravenous Formulation of SCY-078
Oct 7, 2015 4:30 pm EDT SCYNEXIS Appoints Rajeshwar Motheram as Vice President, Pharmaceutical Development
Sep 21, 2015 8:30 am EDT SCYNEXIS Presents Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015
Sep 10, 2015 8:30 am EDT SCYNEXIS to Present Data at ICAAC/ICC 2015 for Novel Antifungal Drug Candidate
